Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurice de Wit

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Ebiomedicine|June 9, 2020
Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitorsMaurice de Wit, Ya Gao, Darlene Mercieca, et al.
Neuro-Oncology Advances|February 17, 2025
Transcriptomic analysis of <i>EGFR</i> co-expression and activation in glioblastoma reveals associations with its ligandsSantoesha A Ghisai, Nastaran Barin, Levi van Hijfte, et al.
Small (Weinheim an Der Bergstrasse, Germany)|October 7, 2022
3D-Engineered Scaffolds to Study Microtubes and Localization of Epidermal Growth Factor Receptor in Patient-Derived Glioma CellsNastaran Barin, Hayri E Balcioglu, Iris de Heer, et al.
Journal of Neuro-Oncology|February 20, 2015
Tumor-specific mutations in low-frequency genes affect their functional propertiesLale Erdem-Eraslan, Daphne Heijsman, Maurice de Wit, et al.
Plos One|June 29, 2018
IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysisYa Gao, Maurice de Wit, Eduard A Struys, et al.
Neuro-Oncology Advances|July 10, 2020
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligandYouri Hoogstrate, Wies Vallentgoed, Johan M Kros, et al.
Cancer Research|January 15, 2016
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB TrialLale Erdem-Eraslan, Martin J van den Bent, Youri Hoogstrate, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 25, 2023
Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohortMerel C Broers, Luuk Wieske, Ece Erdag, et al.
Science Immunology|June 23, 2022
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinctAnna Z Mykytyn, Melanie Rissmann, Adinda Kok, et al.
Cell Stem Cell|May 6, 2022
Human branching cholangiocyte organoids recapitulate functional bile duct formationFloris J M Roos, Gilles S van Tienderen, Haoyu Wu, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Ebiomedicine|June 9, 2020
Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitorsMaurice de Wit, Ya Gao, Darlene Mercieca, et al.
Neuro-Oncology Advances|February 17, 2025
Transcriptomic analysis of <i>EGFR</i> co-expression and activation in glioblastoma reveals associations with its ligandsSantoesha A Ghisai, Nastaran Barin, Levi van Hijfte, et al.
Small (Weinheim an Der Bergstrasse, Germany)|October 7, 2022
3D-Engineered Scaffolds to Study Microtubes and Localization of Epidermal Growth Factor Receptor in Patient-Derived Glioma CellsNastaran Barin, Hayri E Balcioglu, Iris de Heer, et al.
Journal of Neuro-Oncology|February 20, 2015
Tumor-specific mutations in low-frequency genes affect their functional propertiesLale Erdem-Eraslan, Daphne Heijsman, Maurice de Wit, et al.
Plos One|June 29, 2018
IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysisYa Gao, Maurice de Wit, Eduard A Struys, et al.
Neuro-Oncology Advances|July 10, 2020
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligandYouri Hoogstrate, Wies Vallentgoed, Johan M Kros, et al.
Cancer Research|January 15, 2016
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB TrialLale Erdem-Eraslan, Martin J van den Bent, Youri Hoogstrate, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 25, 2023
Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohortMerel C Broers, Luuk Wieske, Ece Erdag, et al.
Science Immunology|June 23, 2022
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinctAnna Z Mykytyn, Melanie Rissmann, Adinda Kok, et al.
Cell Stem Cell|May 6, 2022
Human branching cholangiocyte organoids recapitulate functional bile duct formationFloris J M Roos, Gilles S van Tienderen, Haoyu Wu, et al.
Pageof 2